DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for articular cartilage disorder — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleArticular cartilage disorder maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for articular cartilage disorder is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
retinoic acid receptor gamma (RARG) — RARG is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1-adamantyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6FX0 · 1.9 Å · ligand 6-[3-(1-adamantyl)-4-oxidanyl-phenyl]naphthalene-2-carboxylic acid (E9T). Experimental structure, not a prediction.
What the evidence adds up to
A 2007 review of the molecular basis of cartilage homeostasis describes osteoarthritis as a disruption of the balance between anabolic and catabolic signals, noting that joint formation is regulated by growth factors such as Wnts and Gdfs. The review states that symptomatic treatments and surgical joint replacement are effective but can be problematic for quality of life over time. No clinical data from trials are presented in this review.
A 2018 review of clinical articular cartilage repair reiterates that articular cartilage has very limited self-renewal capacity due to avascularity and lack of innervation. It notes that disturbed joint homeostasis after trauma may induce generalised cartilage loss with risk of progression to osteoarthritis. The review presents non-operative and surgical treatments but does not report any quantitative outcomes such as survival or response rates from specific interventions.
A 1998 paper on autologous chondrocyte implantation (ACI) states that articular cartilage, once destroyed, will not regenerate and that lesions may progress to osteoarthritis, causing pain, swelling, and mechanical symptoms. The paper reports that ACI has generated substantial interest since its introduction in Sweden more than 10 years prior, but provides no numerical data on success rates, sample sizes, or long-term outcomes from any trial.
What is still missing: no randomised controlled trial data comparing any drug or cell therapy against placebo or standard care for articular cartilage disorder is presented in these abstracts. There is no evidence of a repurposed drug being tested in patients. The field lacks adequately powered trials with defined patient stratification, long-term follow-up, and funding for comparative effectiveness studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Medicinal Research Reviews · 2007 · 112 citations
Molecular network of cartilage homeostasis and osteoarthritis
AbstractThis review article presents the current understanding of the molecular basis of articular cartilaginous homeostasis, and outlines potential areas to focus on within the developing field of therapeutics for cartilage disorders. Articular cartilage, an integral component of joints in extremities and the vertebral column, is essential for locomotion. Disturbance of joint development or cartilage homeostasis causes congenital osteocartilaginous dysplasia or osteoarthritic diseases, respectively. Symptomatic treatments and surgical replacement of joints are effective but can also be problematic in terms of quality of life over time. Recently, new insights into the molecular biological basis of chondrocyte differentiation and cartilage homeostasis have been reported. While joint formation is regulated by several growth factors such as Wnts (wingless-related MMTV integration site) and Gdfs (growth and differentiation factors), the pathology of osteoarthritis is now interpreted as the disruption of balance between anabolic and catabolic signals. Current findings in molecular biology on joint development are reviewed concisely to aid in the understanding of the molecular network that governs articular cartilage development and homeostasis.
Annals of Joint · 2018 · 34 citations · open access
Clinical articular cartilage repair—an up to date review
AbstractArticular cartilage is a tissue with very limited self-renewal capacity due to its avascularity and lack of innervation. Many people develop severe disability after chondral and osteochondral traumatic injuries and there exist several options to treat such injuries in order to reduce pain and restore joint homeostasis. A disturbed joint homeostasis after joint trauma may induce generalized loss of cartilage with a risk of progression into a full organ disease: osteoarthritis. Repair long-term durability seems to be an important factor when to choose the right type of treatment. In this review, current non-operative and surgical treatments are presented and their possible place in the treatment toolbox is discussed.
Autologous Chondrocyte Implantation: Current State-of-the-Art
AbstractSince its introduction in Sweden more than 10 years ago, autologous chondrocyte implantation (ACI) has generated substantial interest in the orthopedic community. The high level of interest in ACI is likely do to the troublesome nature of the articular cartilage lesions. It is designed to treat: once destroyed, articular cartilage will not regenerate, and lesions may progress to osteoarthritis. Furthermore, these lesions frequently result in pain, swelling, and mechanical symptoms such as locking and catching, dramatically reducing patient’s quality-of-life.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
